The present invention is directed to caprolactams which are positive allosteric modulators of metabotropic glutamate receptors, particularly the mGluR5 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
本发明涉及己内酰胺,其为代谢型谷
氨酸受体的正向变构调节剂,特别是mGluR5受体,并且在治疗或预防与谷
氨酸功能障碍相关的神经和精神障碍以及代谢型谷
氨酸受体涉及的疾病中有用。本发明还涉及包含这些化合物的药物组合物以及将这些化合物和组合物用于预防或治疗涉及代谢型谷
氨酸受体的这种疾病。